Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

Nature Communications

Volumn 6, Issue , 2015, Pages

  Kovac, Michal ^a,b   Navas, Carolina ^c   Horswell, Stuart ^c   Salm, Max ^c   Bardella, Chiara ^a   Rowan, Andrew ^c   Stares, Mark ^c   Castro Giner, Francesc ^a   Fisher, Rosalie ^c   De Bruin, Elza C ^d   Kovacova, Monika ^e   Gorman, Maggie ^a   Makino, Seiko ^a   Williams, Jennet ^a   Jaeger, Emma ^a   Jones, Angela ^a   Howarth, Kimberley ^a   Larkin, James ^f   Pickering, Lisa ^f   Gore, Martin ^f   Nicol, David L ^f,g   Hazell, Steven ^f   Stamp, Gordon ^c   O'Brien, Tim ^h   Challacombe, Ben ^h   Matthews, Nik ^c   Phillimore, Benjamin ^c   Begum, Sharmin ^c   Rabinowitz, Adam ^c   Varela, Ignacio ⁱ   Chandra, Ashish ^h   Horsfield, Catherine ^h   Polson, Alexander ^h   Tran, Maxine ^j   Bhatt, Rupesh ^k   Terracciano, Luigi ^l   Eppenberger Castori, Serenella ^l   Protheroe, Andrew ^m   Maher, Eamonn ^j   El Bahrawy, Mona ⁿ   Fleming, Stewart ^o   Ratcliffe, Peter ^p,q   Heinimann, Karl ^b   Swanton, Charles ^c,d   Tomlinson, Ian ^a,b,c   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF CANTABRIA   (Spain)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k The Liver Unit   (United Kingdom)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁿ HAMMERSMITH HOSPITAL   (United Kingdom)

^o UNIVERSITY OF DUNDEE   (United Kingdom)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARID2 PROTEIN; BAP1 PROTEIN; CUL3 PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NFE2L2 PROTEIN; PBRM1 PROTEIN; RETINOBLASTOMA BINDING PROTEIN 2; SUNITINIB; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; HISTONE LYSINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY; SET2 PROTEIN, HUMAN;

CANCER; CHROMOSOME; GENE EXPRESSION; GERM CELL; MUTATION; PATHOLOGY;

ADULT; AGED; ARTICLE; CHROMOSOME 12; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; EXOME; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOME; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; TUMOR GENE; VERY ELDERLY; CHEMISTRY; CHROMOSOME; CHROMOSOME MAP; COPY NUMBER VARIATION; DNA SEQUENCE; EXON; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; KIDNEY TUMOR; MIDDLE AGED; MUTATION; PHYLOGENY; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRASTRUCTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; CHROMOSOME MAPPING; CHROMOSOMES; DNA COPY NUMBER VARIATIONS; EXOME; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84925267081     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7336     Document Type: Article

References (46)

1. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993).
2. Keefe, S. M., Nathanson, K. L. & Rathmell, W. K. The molecular biology of renal cell carcinoma. Semin. Oncol. 40, 421-428 (2013).
3. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73 (1997).
4. Tomlinson, I. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406-410 (2002).
5. Nickerson, M. L. et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2, 157-164 (2002).
6. Cheng, L. et al. Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma. Clin. Cancer Res. 14, 8087-8093 (2008).
7. Jones, T. D. et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin. Cancer Res. 11, 7226-7233 (2005).
8. Junker, K. et al. Clonal origin of multifocal renal cell carcinoma as determined by microsatellite analysis. J Urol 168, 2632-2636 (2002).
9. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
10. Twardowski, P. W., Mack, P. C. & Lara, Jr. P. N. Papillary renal cell carcinoma: current progress and future directions. Clin. Genitourin. Cancer 12, 74-79 (2014).
11. Foster, K. et al. Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br. J. Cancer 69, 230-234 (1994).
12. Bentz, M. et al. Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenet. Cell Genet. 75, 17-21 (1996).
13. Hughson, M. D., Dickman, K., Bigler, S. A., Meloni, A. M. & Sandberg, A. A. Clear-cell and papillary carcinoma of the kidney: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification, cytogenetics, and fluorescence in situ hybridization. Cancer Genet. Cytogenet. 106, 93-104 (1998).
14. Jiang, F. et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am. J. Pathol. 153, 1467-1473 (1998).
15. Junker, K. et al. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res. 162, 169-175 (2003).
16. Kardas, I. et al. Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas. Oncol. Rep. 13, 949-956 (2005).
17. Furge, K. A. et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 67, 3171-3176 (2007).
18. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
19. Drmanac, R. et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81 (2010).
20. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
21. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
22. Shen, M. M. Chromoplexy: a new category of complex rearrangements in the cancer genome. Cancer Cell 23, 567-569 (2013).
23. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
24. Li, M. et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828-829 (2011).
25. Kinch, L., Grishin, N. V. & Brugarolas, J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 20, 418-420 (2011).
26. Adam, J. et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524-537 (2011).
27. Ooi, A. et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res. 73, 2044-2051 (2013).
28. Gonzalez-Perez, A. et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat. Methods 10, 1081-1082 (2013).
29. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
30. Glukhova, L. et al. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene. Oncogene 19, 754-761 (2000).
31. Albiges, L. et al. MET is a potential target across all Papillary Renal Cell Carcinomas. Result from a large molecular study of pRCC with CGHa and matching Gene Expression array. Clin. Cancer Res. 20, 3411-3421 (2014).
32. Sidhar, S. K. et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum. Mol. Genet. 5, 1333-1338 (1996).
33. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396-398 (2014).
34. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
35. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
36. Tamborero, D. et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci. Rep. 3, 2650 (2013).
37. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
38. Ooi, A. & Furge, K. A. Fumarate hydratase inactivation in renal tumors: HIF1alpha, NRF2, and 'cryptic targets' of transcription factors. Chin. J. Cancer 31, 413-420 (2012).
39. Brugarolas, J. Molecular genetics of clear-cell renal cell carcinoma. J. Clin. Oncol. 32, 1968-1976 (2014).
40. Moore, L. E. et al. Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation. Oncogenesis 1, e14 (2012).
41. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
42. Cazier, J. B. et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat. Commun. 5, 3756 (2014).
43. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
44. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
45. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
46. Tamura, K., Stecher, G., Peterson, D., Filipski, A. & Kumar, S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol. Biol. Evol. 30, 2725-2729 (2013).